Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela
Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a total
number of 11,840 RSUs that were issued to them in June 2018 after they had
elected to receive all or part of their remuneration for the period from the
annual general meeting in 2018 to the annual general meeting in 2019 in RSUs. In
addition, a former board member has resolved to settle a total number of 7,000
RSUs that the Company has previously issued as remuneration under the RSU
-program. Each RSU gives the right to subscribe for one share in the Company at
a subscription price of NOK 0.20.

The Board of Directors of the Company has, to fulfil the Company's obligations
under the RSU agreements, resolved to issue 18,840 new shares at a subscription
price of NOK 0.20 per share giving a total subscription amount of NOK 3,768. The
shares are issued pursuant to the authorisation granted to the Board of
Directors at the annual general meeting held on 25 April 2019. Subsequent to the
issuance of the new shares, the Company's share capital will be NOK
10,941,288.60 divided into 54,706,443 shares, each with a nominal value of NOK
0.20.

Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari have subscribed for 5,732
new shares, 4,072 new shares and 2,036 new shares respectively. The three board
members will following issuance of the new shares, have the following holding of
shares and RSUs in the Company:

+-------------------+--------------------+----------------------+
|Name               |Total number of RSUs|Total number of shares|
+-------------------+--------------------+----------------------+
|Gisela Schwab      |2,331               |15,732                |
+-------------------+--------------------+----------------------+
|Joanna Horobin     |4,953               |8,857                 |
+-------------------+--------------------+----------------------+
|Jean-Pierre Bizzari|2,477               |6,545                 |
+-------------------+--------------------+----------------------+

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to section 3.2 of
the continuing obligations for listed companies.